- Home
- IOR vs LSB Comparison
IOR vs LSB Comparison
Compare IOR & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOR
- LSB
- Stock Information
- Founded
- IOR 1984
- LSB 2002
- Country
- IOR United States
- LSB China
- Employees
- IOR N/A
- LSB N/A
- Industry
- IOR Real Estate Investment Trusts
- LSB
- Sector
- IOR Real Estate
- LSB
- Exchange
- IOR Nasdaq
- LSB NYSE
- Market Cap
- IOR 73.2M
- LSB 71.2M
- IPO Year
- IOR N/A
- LSB N/A
- Fundamental
- Price
- IOR $17.95
- LSB $2.51
- Analyst Decision
- IOR
- LSB
- Analyst Count
- IOR 0
- LSB 0
- Target Price
- IOR N/A
- LSB N/A
- AVG Volume (30 Days)
- IOR 1.3K
- LSB 29.0K
- Earning Date
- IOR 11-07-2024
- LSB 12-19-2024
- Dividend Yield
- IOR N/A
- LSB N/A
- EPS Growth
- IOR 5.46
- LSB N/A
- EPS
- IOR 1.47
- LSB N/A
- Revenue
- IOR N/A
- LSB $79,415,311.00
- Revenue This Year
- IOR N/A
- LSB $39.33
- Revenue Next Year
- IOR N/A
- LSB $75.61
- P/E Ratio
- IOR $12.28
- LSB N/A
- Revenue Growth
- IOR N/A
- LSB N/A
- 52 Week Low
- IOR $13.80
- LSB $1.88
- 52 Week High
- IOR $19.00
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- IOR 52.47
- LSB 42.95
- Support Level
- IOR $17.83
- LSB $2.31
- Resistance Level
- IOR $18.10
- LSB $2.83
- Average True Range (ATR)
- IOR 0.14
- LSB 0.37
- MACD
- IOR -0.06
- LSB -0.09
- Stochastic Oscillator
- IOR 20.59
- LSB 18.37
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. Its business is managed by Pillar Income Asset Management, Inc. Pillar's duties include, but are not limited to, locating, evaluating and recommending real estate and real estate-related investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.